Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
for Biliary Tract Cancer
Sites in Nashville +5 more locations
Sponsor: ModeX Therapeutics, An OPKO Health Company
Sex: All·Age: 18+
Code: NCT06239194·Phase 1, Phase 2·Recruiting·Listed Feb 2024